EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis

Folke Folkvaljon, Morie Gertz, Julian D Gillmore, Sami Khella, Ahmad Masri, Mathew S Maurer, Márcia Waddington Cruz, Jonas Wixner, Jersey Chen, Barry Reicher, Jesse Kwoh, Aaron Yarlas und 1 weitere

Muscle & Nerve · 2025

DOI: 10.1002/mus.28299 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Folke Folkvaljon und 12 weiteren Autor:innen. Beteiligte Einrichtung: HTA Statistics & Data Science, BioPharmaceuticals Medical, AstraZeneca, Barcelona, Spain. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Quality of Life, Nutritional Status. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca, Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims The degree of change in neuropathic impairment and quality of life (QoL) that is clinically meaningful to patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‐PN) is not established. This study aimed to estimate the magnitude of treatment differences that are meaningful to patients in measures of neuropathy and QoL and to determine whether eplontersen achieved a meaningful improvement versus placebo.

Methods

Data from the NEURO‐TTRansform trial on patients with ATTRv‐PN treated with eplontersen ( n = 141) or historical placebo ( n = 59) were used. Anchor‐based approaches were used to estimate thresholds for meaningful differences in the modified Neuropathy Impairment Score +7 (mNIS+7) composite score, Norfolk QoL‐Diabetic Neuropathy (Norfolk QoL‐DN) total score, Neuropathy Symptoms and Change (NSC) total score, and modified body mass index (mBMI). Differences between the least squares means of the treatment groups were analyzed.

Results

Meaningful improvement in mNIS+7 was estimated as −4.0 points and deterioration as 1.8 points. The estimated ranges of meaningful improvement and deterioration in Norfolk QoL‐DN were −12.8 to −4.0 points, and 5.9 to 14.7 points, respectively. For NSC, ranges were −2.4 to −1.3 points for meaningful improvement, and 0.6 to 5.8 points for deterioration. The estimated meaningful improvement in mBMI was 9.8 kg/m 2 × g/L and deterioration was −40.9 kg/m 2 × g/L. Improvements in each measure with eplontersen versus placebo were greater than the estimates of meaningful differences.

Discussion

Eplontersen demonstrated a clinically meaningful effect on neuropathic impairment, QoL, and nutritional status. Such estimates have implications for clinical practice and trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialQuality of LifeNutritional StatusHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodPolyneuropathies

Stichwörter der Autor:innen

anchor‐based estimatesantisense oligonucleotideeplontersenhereditary transthyretin amyloidosis with polyneuropathymeaningful difference

Autor:innen und Institutionen

  • HTA Statistics & Data Science, BioPharmaceuticals Medical, AstraZeneca, Barcelona, Spain.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • National Amyloidosis Centre, University College London, Royal Free Hospital, London, UK.
  • University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
  • OHSU Center for Hypertrophic Cardiomyopathy and Amyloidosis, Portland, Oregon, USA.
  • Columbia University Irving Medical Center, New York, New York, USA.

ORCID-Profile: John L Berk

Förderung

  • AstraZeneca
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals

Zitieren

APA

Folkvaljon, F., Gertz, M., Gillmore, J. D., Khella, S., Masri, A., Maurer, M. S., Cruz, M. W., Wixner, J., Chen, J., Reicher, B., Kwoh, J., Yarlas, A., & Berk, J. L. (2025). Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle & Nerve. https://doi.org/10.1002/mus.28299

Vancouver

Folkvaljon F, Gertz M, Gillmore JD, Khella S, Masri A, Maurer MS, et al. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle & Nerve. 2025. doi:10.1002/mus.28299

BibTeX
@article{Folkvaljon2025,
  author = {Folkvaljon, Folke and Gertz, Morie and Gillmore, Julian D and Khella, Sami and Masri, Ahmad and Maurer, Mathew S and Cruz, Márcia Waddington and Wixner, Jonas and Chen, Jersey and Reicher, Barry and Kwoh, Jesse and Yarlas, Aaron and Berk, John L},
  title = {Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis},
  journal = {Muscle & Nerve},
  year = {2025},
  doi = {10.1002/mus.28299}
}
Kostenlos starten →